The DxS Team

Management Team

Chief Executive Officer: Dr Stephen Little Dr. Steve Little has over 20 years' experience in the biotechnology industry and was a board and executive team member during his 11 years at AstraZeneca Diagnostics. He had overall responsibility for the scientific strategy of the business. Dr.Little has extensive experience in the development of nucleic acid based diagnostic products and services for human genetic analysis. The Diagnostics business was in the forefront of the human genetics analysis market and DxS benefits from the accumulated technical, regulatory and commercial know-how gained from many years experience as an early mover in this sector. Stephen.Little@dxsgenotyping.com

Chief Scientific Officer: Dr David Whitcombe Dr. David Whitcombe was with AstraZeneca Diagnostics for 5 years where he headed the technology development group. He was the inventor of the Scorpions system and led the development of the key technologies used by DxS. He has over 15 years experience in genetic research and development. David.Whitcombe@dxsgenotyping.com     Sales and Marketing Director: Andrew Webb Andrew Webb was with Amersham Pharmacia Biotech for 11 years most recently as sales director responsible for licensing their proprietary technologies in genomics, proteomics and drug screening in Europe. He spent 5 years in drug metabolism at SmithKline Beecham prior to joining Amersham where his varied career encompassed key account management for customers in the pharmaceutical industry and subsequently sales management. Andrew.Webb@dxsgenotyping.com     Business Development Director: Peter Collins Peter brings over 20 years of experience in the Diagnostics and Life Sciences industry. He brings a breadth of knowledge and contacts having worked in the large corporate environment with BD Biosciences and Syva (Syntex), the established SME’s of Vysis (Abbott) and Biogenex. He has also served as executive director and a board member in a range of early stage companies, Quantase (Biorad), Gentronix and Pronostics. Peter has spent many years with leading edge products in the molecular pathology arena. Peter.Collins@dxsgenotyping.com     Finance Director Derek Bannister Derek qualified as a Chartered Accountant (KPMG) in 1980. He has been Finance Director of a variety of companies for over 20 years, working across various sectors including Marketing, Training and Pharma support companies. He was most recently involved in the MBO and subsequent very successful trade sale of Medeval, a Phase 1 clinical research organisation, based in Manchester. His experience has been gained mainly in SME’s helping these businesses maximise their potential and shareholder value. Derek.Bannister@dxsgenotyping.com       Key Staff Quality & Regulatory Manager Chris Bray Chris Bray previously worked for Imutran Limited (A Novartis Pharma AG Company) and has over nine years experience working in Quality and Regulatory environments within the Healthcare Industry. He has a strong technical background and extensive experience in the auditing, design and implementation of Quality Systems. Chris.Bray@dxsgenotyping.com     Laboratory Manager Paul Ravetto Paul Ravetto has had over ten years experience in genetics research and development. He trained at the Roslin Institute and prior to joining DxS held posts at the Institute of Ophthalmology and the University of Manchester where he was involved in projects investigating the genetics of childhood leukaemia. Paul has extensive technical and research experience, which enables him to carry out his role as the Laboratory Manager and ensure that projects are carried out on time and to the required high standards. Paul.Ravetto@dxsgenotyping.com     Product Development Manager Dr Nicky Thelwell Nicky Thelwell has 8 years experience in the Biotechnology Industry, having worked for Oswel/Eurogentec before joining DxS.  Nicky has a proven track record in technology development and evaluation. She has previously worked with customers to develop numerous diagnostic assays. Her background in both research and industry, and her knowledge of diagnostic development process make her ideally suited for the role of Product Development Manager.  Nicola.thelwell@dxsgenotyping.com     Project Manager Dr Steven Wolfenden Steven has gained technical experience in the pharmaceutical industry working in the areas of dry powder inhalers and sterile products at Ashton Pharmaceuticals Limited (APL). More recently he has been one of two project managers at APL responsible for new product introduction at their manufacturing and packing facility. As a project manager at APL, Steven was the primary customer interface between the project team and the client, in the areas of manufacture for clinical trials, solid dose and sterile products.   Steven.wolfenden@dxsgenotyping.com